Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 166

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections

Open access
Neuner, Elizabeth A., Yeh, Jun-Yen, Hall, Gerri S., Sekeres, Jennifer, Endimiani, Andrea, Bonomo, Robert A., Shrestha, Nabin K., Fraser, Thomas G., van Duin, David·2011·Diagnostic Microbiology and Infectious Disease

Abstract

Carbapenem-resistant K. pneumoniae (CR-Kp) is an emerging multi-drug resistant nosocomial pathogen. This is a retrospective chart review describing the outcomes and treatment of 60 cases of CR-Kp bloodstream infections. All CR-Kp isolated from blood cultures were identified retrospectively from the microbiology laboratory from January 2007 to May 2009. Clinical information was collected from the electronic medical record. Patients with 14 day-hospital mortality were compared to those who survived 14 days. The all-cause in-hospital and 14-day mortality for all 60 CR-Kp bloodstream infections was 58.3% and 41.7%, respectively. In this collection, 98% of tested isolates were susceptible in vitro to tigecycline, compared to 86% to colistimethate, 45% to amikacin and 22% to gentamicin. Nine patients died prior to cultures being finalized, and received no therapy active against CR-Kp. In the remaining 51 patients, those who survived to day14 (n=35) were compared to non-survivor at day 14 (n=16). These patients were characterized by both chronic disease and acute illness. The 90-day readmission rate for hospital survivors was 72%. Time to active therapy was not significantly different between survivors and non-survivors, and hospital mortality was also similar regardless of therapy chosen. Pitt bacteremia score was the only significant factor associated with mortality in Cox regression analysis. In summary, CR-Kp bloodstream infections occur in patients who are chronically and acutely ill. They are associated with high 14-day mortality and poor outcomes regardless of tigecycline or other treatment regimens were selected.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.diagmicrobio.2010.10.013

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 166

Metadata

Authors
Neuner, E. A., Yeh, J.-Y., Hall, G. S., Sekeres, J., Endimiani, A., Bonomo, R. A., Shrestha, N. K., Fraser, T. G., & van Duin, D.
Venue
Diagnostic Microbiology and Infectious Disease
Publisher
Elsevier BV
Published
2011-04
Volume
69
Issue
4
Pages
357-362
ISSN
0732-8893 (ISSN-L)
OpenAlex
W1976159940
Cited by
166
References
1
FWCI
5.92
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections. https://app.cochat.ai/papers/10.1016/j.diagmicrobio.2010.10.013
The paper
Neuner, E. A., Yeh, J.-Y., Hall, G. S., Sekeres, J., Endimiani, A., Bonomo, R. A., Shrestha, N. K., Fraser, T. G., & van Duin, D. (2011). Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Diagnostic Microbiology and Infectious Disease. https://doi.org/10.1016/j.diagmicrobio.2010.10.013

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.